Hexarelin vs IGF-1 DES
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Examorelin, HEX
Hexarelin is a synthetic six-amino-acid peptide (a growth hormone-releasing peptide, or GHRP) that pushes the pituitary to release growth hormone. What makes it more interesting than its cousins is a second job: it binds a receptor in heart tissue and appears to protect the heart, an effect that does not depend on growth hormone at all. It is a research compound, not an approved drug, and almost all of the heart data is from animals.
Also: des(1-3)IGF-1, Des(1-3) IGF-I
IGF-1 DES is insulin-like growth factor 1 with its first three amino acids chopped off, leaving a 67-residue peptide. That small cut makes it bind poorly to the IGF binding proteins that normally keep IGF-1 in check, so more of it reaches the receptor and it acts stronger, but shorter. It occurs naturally in small amounts (it was first isolated from human fetal brain tissue) and is sold online as a muscle-building research peptide. There are no human trials of it at all, so everything said about it in people is extrapolation.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Hexarelin has stronger research evidence (Human Trials) compared to IGF-1 DES (Preclinical).
Detailed Comparison
| Attribute | Hexarelin | IGF-1 DES |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Hexarelin acts through two different receptors, which is the key to understanding it. The first is the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor in the pituitary, which is how it triggers growth hormone release. The second is CD36, a scavenger receptor found on heart muscle cells and small blood vessels, and this is where its cardioprotective story lives. Activating CD36 in the heart has been shown to improve coronary flow and protect heart tissue from ischemia (low oxygen) and reperfusion injury, and crucially these effects still happen in growth-hormone-deficient animals, proving the heart benefit is separate from the GH benefit. | Like regular IGF-1, des(1-3)IGF-1 activates the type 1 IGF receptor, a tyrosine kinase receptor closely related to the insulin receptor. That switches on PI3K/Akt and MAPK signalling, which drives cell growth, protein synthesis and glucose uptake. The difference is the binding proteins. In the body almost all IGF-1 rides around bound to IGFBPs, which limit how much can hit the receptor. Removing the N-terminal tripeptide (Gly-Pro-Glu) sharply weakens IGFBP binding while leaving receptor binding intact. In a 1992 JCI study on rat granulosa cells, des(1-3)IGF-1 was about 10 times more potent than intact IGF-1 when binding proteins were present, and roughly equal once they were removed, which shows the extra potency comes from dodging the binding proteins rather than a stronger receptor hit. The trade-off: unbound IGF-1 is cleared fast, so its action is short and local, which is why people inject it into a specific muscle. It also carries IGF-1's insulin-like effect on blood sugar. |
| Common Dosing | 100-200 mcg 2-3x daily 2-3x daily | Community-reported 20-100 mcg per day Usually once daily on training days |
| Administration | Subcutaneous injection | Intramuscular or subcutaneous injection (community practice); studied by injection in animals only |
| Typical Duration | 4-8 weeks (desensitization occurs) | Community reports describe short cycles of about 4-6 weeks; there is no human data on safe duration |
| Best Time to Take | Morning and before bed (fasted) | Around training, per community practice |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The growth hormone-releasing effect of hexarelin is well established in humans from older endocrine research, but the exciting cardiovascular claims are still mostly preclinical. The landmark mechanistic work (Circulation Research, 2002) identified CD36 as the receptor through which growth hormone-releasing peptides act on the heart, and follow-up rodent studies showed hexarelin improves left ventricular function and protects cardiomyocytes from ischemia-reperfusion injury, in one case through interleukin-1 signaling (2017). A 2014 review in the Annals of the New York Academy of Sciences and a 2017 PMC review both lay out a plausible cardioprotective case. But here is the honest part: there are no large modern human trials showing hexarelin treats or prevents heart disease in people, and a known limitation is rapid tolerance, the GH response fades with continued use. So the cardiac angle is genuinely interesting biology, not an established therapy. | The research is old, small, and entirely in cells and animals. Sara, Carlsson-Skwirut and colleagues isolated a truncated variant of IGF-1 from human fetal brain in 1986 (PNAS). In GH-deficient lit/lit mice, Gillespie and colleagues (J Endocrinol, 1990) found that 3 microgram daily injections of des(1-3)IGF-1 increased body length about as much as 30 micrograms of regular IGF-1, confirming its higher potency in a living animal; organ weights (kidney, heart) also rose. Adashi and colleagues (JCI, 1992) showed the roughly 10-fold potency gain disappears when IGF binding proteins are removed. Beyond that, it is mostly a lab tool for studying the IGF system. There are no human trials, no pharmacokinetic data in people, and no safety data. Claims about local muscle hyperplasia, fat loss, or recovery are bodybuilding lore built on IGF-1 biology, not on studies of this peptide. Theoretical risks are the same as for IGF-1 and other analogues: low blood sugar, and long-term concerns about feeding the growth of existing tumours, since IGF-1 signalling is a known growth pathway in several cancers. Quality is another unknown: the material sold online has no pharmaceutical oversight. |
Frequently Asked Questions: Hexarelin vs IGF-1 DES
What is the difference between Hexarelin and IGF-1 DES?
Hexarelin is a growth hormone peptide that hexarelin is a synthetic six-amino-acid peptide (a growth hormone-releasing peptide, or ghrp) that pushes the pituitary to release growth hormone. what makes it more interesting than its cousins is a second job: it binds a receptor in heart tissue and appears to protect the heart, an effect that does not depend on growth hormone at all. it is a research compound, not an approved drug, and almost all of the heart data is from animals. IGF-1 DES is a growth hormone peptide that igf-1 des is insulin-like growth factor 1 with its first three amino acids chopped off, leaving a 67-residue peptide. that small cut makes it bind poorly to the igf binding proteins that normally keep igf-1 in check, so more of it reaches the receptor and it acts stronger, but shorter. it occurs naturally in small amounts (it was first isolated from human fetal brain tissue) and is sold online as a muscle-building research peptide. there are no human trials of it at all, so everything said about it in people is extrapolation. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Hexarelin or IGF-1 DES?
Neither is universally "better" - the choice depends on your specific goals. Hexarelin is typically used for growth hormone purposes, while IGF-1 DES is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Hexarelin and IGF-1 DES be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Hexarelin and IGF-1 DES together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.